you said, dr. lyke, you would see early results in august, but this study goes on for you think four years. guest: correct. we are adding new groups and boosters as we go. all the companies and groups making boosters targeted toward some of the variants, for instance, the south african variant, so we hope to be testing those boosters as well, but as new products come along, we will add them into our study. host: the individuals being studied, how does this work? you get the booster and how does in ih, how does your group -- how does nih, your group, determine the efficacy? guest: this is all about immune response and safety, not so much efficacy. we are assuming that all the massive trials with 30,000 to 40,000 have already proved these vaccines work, so our objective is to look at the immune response and to compare it to people that, according to their previous response after they got their initial dosing. so we are enrolling people at 10 sites throughout the u.s. and asking them to donate blood so tha